Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology. All examined agents decreased the degree of hyperplasia in acinar epithelium; the greatest efficacy was demonstrated by prostagenin. Moreover, dihydroquercetin and p-thyrozol increased the cross-section area of acinar lumina and prostate volume, which is inadmissible in this pathology. These results suggest that the use of phenolic antioxidants in the therapy of benign prostatic hyperplasia should be strictly controlled.

Sobre autores

T. Borovskaya

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Autor responsável pela correspondência
Email: repropharm@yandex.ru
Rússia, Tomsk

S. Kamalova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

V. Grigor’eva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

M. Poluektova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

A. Vychuzhanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

A. Kuchin

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Rússia, Syktyvkar

I. Chukicheva

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Rússia, Syktyvkar

E. Buravlev

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Rússia, Syktyvkar

T. Fomina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

M. Plotnikov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

V. Goldberg

Research Institute of Oncology, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk

A. Dygai

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Rússia, Tomsk


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies